HK1256886A1 - 包含治療劑的治療性納米顆粒及其製備和使用方法 - Google Patents
包含治療劑的治療性納米顆粒及其製備和使用方法Info
- Publication number
- HK1256886A1 HK1256886A1 HK18115987.3A HK18115987A HK1256886A1 HK 1256886 A1 HK1256886 A1 HK 1256886A1 HK 18115987 A HK18115987 A HK 18115987A HK 1256886 A1 HK1256886 A1 HK 1256886A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- therapeutic
- making
- methods
- same
- nanoparticles
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562248551P | 2015-10-30 | 2015-10-30 | |
PCT/US2016/059349 WO2017075369A1 (en) | 2015-10-30 | 2016-10-28 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1256886A1 true HK1256886A1 (zh) | 2019-10-04 |
Family
ID=58630840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18115987.3A HK1256886A1 (zh) | 2015-10-30 | 2018-12-13 | 包含治療劑的治療性納米顆粒及其製備和使用方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20180311177A1 (zh) |
EP (1) | EP3368021A4 (zh) |
JP (1) | JP2018533574A (zh) |
KR (1) | KR20180054855A (zh) |
CN (1) | CN108174597A (zh) |
AU (1) | AU2016343662A1 (zh) |
BR (1) | BR112018006870A2 (zh) |
CA (1) | CA3003280A1 (zh) |
HK (1) | HK1256886A1 (zh) |
IL (1) | IL259047A (zh) |
MX (1) | MX2018005085A (zh) |
RU (1) | RU2018115566A (zh) |
WO (1) | WO2017075369A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200268679A1 (en) * | 2017-11-03 | 2020-08-27 | The Trustees Of Princeton University | Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations |
KR20200126976A (ko) * | 2018-01-29 | 2020-11-09 | 더 존스 홉킨스 유니버시티 | 단백질 치료제의 캡슐화 및 지속 방출을 위한 중합성 나노입자 조성물 |
RU2717101C1 (ru) * | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
WO2021055467A1 (en) * | 2019-09-16 | 2021-03-25 | University Of Miami | Orally administrable nano-medicine for viral diseases |
US20240122866A1 (en) * | 2021-02-23 | 2024-04-18 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Cationic polymer-formulated nanoparticles and methods of use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008139804A1 (ja) * | 2007-05-14 | 2008-11-20 | Ltt Bio-Pharma Co., Ltd. | 徐放性の陰荷電基を持つ低分子薬物含有ナノ粒子 |
CN104822370A (zh) * | 2012-09-17 | 2015-08-05 | 佰恩德治疗股份有限公司 | 包含治疗剂的治疗性纳米颗粒及其制备和使用方法 |
AP2016009494A0 (en) * | 2014-03-14 | 2016-10-31 | Pfizer | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
ES2872552T3 (es) * | 2014-03-17 | 2021-11-02 | Merck Sharp & Dohme | Nanopartículas poliméricas y métodos de preparación y de uso de las mismas |
-
2016
- 2016-10-28 EP EP16860889.1A patent/EP3368021A4/en not_active Withdrawn
- 2016-10-28 MX MX2018005085A patent/MX2018005085A/es unknown
- 2016-10-28 KR KR1020187012121A patent/KR20180054855A/ko not_active Application Discontinuation
- 2016-10-28 AU AU2016343662A patent/AU2016343662A1/en not_active Abandoned
- 2016-10-28 US US15/771,794 patent/US20180311177A1/en not_active Abandoned
- 2016-10-28 CA CA3003280A patent/CA3003280A1/en active Pending
- 2016-10-28 CN CN201680063687.0A patent/CN108174597A/zh active Pending
- 2016-10-28 JP JP2018521367A patent/JP2018533574A/ja active Pending
- 2016-10-28 BR BR112018006870A patent/BR112018006870A2/pt not_active IP Right Cessation
- 2016-10-28 WO PCT/US2016/059349 patent/WO2017075369A1/en active Application Filing
- 2016-10-28 RU RU2018115566A patent/RU2018115566A/ru not_active Application Discontinuation
-
2018
- 2018-04-30 IL IL259047A patent/IL259047A/en unknown
- 2018-12-13 HK HK18115987.3A patent/HK1256886A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA3003280A1 (en) | 2017-05-04 |
CN108174597A (zh) | 2018-06-15 |
AU2016343662A1 (en) | 2018-04-26 |
MX2018005085A (es) | 2018-08-15 |
EP3368021A4 (en) | 2019-07-31 |
WO2017075369A1 (en) | 2017-05-04 |
IL259047A (en) | 2018-06-28 |
RU2018115566A (ru) | 2019-12-03 |
KR20180054855A (ko) | 2018-05-24 |
US20180311177A1 (en) | 2018-11-01 |
JP2018533574A (ja) | 2018-11-15 |
EP3368021A1 (en) | 2018-09-05 |
BR112018006870A2 (pt) | 2018-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256704A1 (zh) | 包含治療劑的治療性納米粒及其製備和使用方法 | |
ZA201606646B (en) | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | |
GB2554283B (en) | Devices for simulating a function of a tissue and methods of use and manufacturing thereof | |
HK1254909A1 (zh) | 藥物納米粒子的傳送及其使用方法 | |
SG10201406612RA (en) | Mask structures and methods of manufacturing | |
PL3104838T3 (pl) | Terapeutyczne nanocząstki zawierające środki terapeutyczne oraz ich sposoby wytwarzania i zastosowanie | |
EP2999474A4 (en) | THERAPEUTIC AND METHOD OF USE | |
IL282482A (en) | Variants of protoxin-II and methods of use | |
SG11201707816PA (en) | Patient interface and aspects thereof | |
HK1256886A1 (zh) | 包含治療劑的治療性納米顆粒及其製備和使用方法 | |
IL265881A (en) | Inhaler and methods of use thereof | |
IL282508A (en) | Variants of protoxin-II and methods of use | |
IL249894A0 (en) | Targeted medical nanoparticles and methods for their preparation and use | |
HK1256368A1 (zh) | 加利車黴素-抗體-藥物綴合物和使用方法 | |
HK1258056A1 (zh) | 治療性化合物和其使用方法 | |
EP3302433A4 (en) | THERAPEUTIC AGENT NANOPARTICLES COATED WITH PHOSPHOLIPID AND ASSOCIATED METHODS | |
GB201417248D0 (en) | Compostion and methods of treatment | |
IL265971B (en) | Therapeutic materials and methods for their production | |
GB2588276B (en) | Devices for simulating a function of a tissue and methods of use and manufacturing thereof | |
GB201613145D0 (en) | Toy apparatus and methods of manufacture and use thereof |